Tags

Type your tag names separated by a space and hit enter

Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome.
Clin Ther. 1986; 8(3):320-8.CT

Abstract

Forty patients with irritable bowel syndrome were randomly allocated to treatment with octylonium bromide (20 mg TID) or cimetropium bromide (50 mg BID) in a double-blind trial lasting for six weeks. Drugs were taken before meals, according to a double-blind schedule. Clinical evaluations were made of digestive and other symptoms, objective findings (pain at palpation, contracted colon, tympanites), and overall effectiveness of treatment. Statistically significant decreases in severity of abdominal pain and subjective scores for bowel habits were obtained in both groups. The only statistically significant differences between treatments were in nondigestive symptoms (asthenia, palpitations, tremor, headache, etc.), which improved more in the cimetropium bromide group. No severe side effects were observed in either treatment group.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3521859

Citation

Ferrari, A, et al. "Double-blind Study of a New Antimuscarinic, Cimetropium Bromide, in Patients With Irritable Bowel Syndrome." Clinical Therapeutics, vol. 8, no. 3, 1986, pp. 320-8.
Ferrari A, Cavallero M, Spandre M, et al. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Clin Ther. 1986;8(3):320-8.
Ferrari, A., Cavallero, M., Spandre, M., Gemme, C., Rossini, F. P., & Imbimbo, B. P. (1986). Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Clinical Therapeutics, 8(3), 320-8.
Ferrari A, et al. Double-blind Study of a New Antimuscarinic, Cimetropium Bromide, in Patients With Irritable Bowel Syndrome. Clin Ther. 1986;8(3):320-8. PubMed PMID: 3521859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. AU - Ferrari,A, AU - Cavallero,M, AU - Spandre,M, AU - Gemme,C, AU - Rossini,F P, AU - Imbimbo,B P, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 320 EP - 8 JF - Clinical therapeutics JO - Clin Ther VL - 8 IS - 3 N2 - Forty patients with irritable bowel syndrome were randomly allocated to treatment with octylonium bromide (20 mg TID) or cimetropium bromide (50 mg BID) in a double-blind trial lasting for six weeks. Drugs were taken before meals, according to a double-blind schedule. Clinical evaluations were made of digestive and other symptoms, objective findings (pain at palpation, contracted colon, tympanites), and overall effectiveness of treatment. Statistically significant decreases in severity of abdominal pain and subjective scores for bowel habits were obtained in both groups. The only statistically significant differences between treatments were in nondigestive symptoms (asthenia, palpitations, tremor, headache, etc.), which improved more in the cimetropium bromide group. No severe side effects were observed in either treatment group. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/3521859/Double_blind_study_of_a_new_antimuscarinic_cimetropium_bromide_in_patients_with_irritable_bowel_syndrome_ DB - PRIME DP - Unbound Medicine ER -